Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
November 07, 2023 09:15 ET
|
Scopus BioPharma Inc.
DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based...
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
November 02, 2023 09:15 ET
|
Scopus BioPharma Inc.
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet...
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer
November 10, 2022 09:15 ET
|
Scopus BioPharma Inc.
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet...
Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value
October 18, 2022 09:25 ET
|
Scopus BioPharma Inc.
Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus...
Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors
May 05, 2022 08:30 ET
|
Scopus BioPharma Inc.
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet...
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
March 22, 2022 20:30 ET
|
Scopus BioPharma Inc.
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present onTLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology NEW YORK, March 22, 2022 (GLOBE...
Scopus BioPharma Provides Update Following Annual Meeting of Stockholders
January 10, 2022 08:30 ET
|
Scopus BioPharma Inc.
Overwhelming Majority of Shares Voted by Unaffiliated Stockholderswere in Favor of Scopus' Director Nominees Lasters’ Ownership Position and Annual Meeting Results are being Challenged in Court ...
Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster’s Campaign Against the Company
December 17, 2021 08:00 ET
|
Scopus BioPharma Inc.
Latest Legal Claims by Laster Actually Call into Question his Stock Ownership Company Urges Stockholders to Vote “FOR ALL” of the Company’s Director Nominees on the WHITE Proxy Card NEW YORK, Dec. ...
Scopus BioPharma Sends Letter Urging Stockholders to Vote “FOR ALL” of the Company’s Director Nominees on the WHITE Proxy Card
December 07, 2021 08:30 ET
|
Scopus BioPharma Inc.
Company’s Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies Executing Strategy to Create an Industry-Leading Portfolio of...
Scopus BioPharma Announces $9.75 Million Private Placement Priced At-The-Market
November 22, 2021 08:00 ET
|
Scopus BioPharma Inc.
NEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...